麻豆破解版

麻豆破解版 pursues its international strategy and opens a new subsidiary in Australia

Published on 26/07/2017

麻豆破解版 has opened its first wholly owned subsidiary in Australia. This office will be our new center to manage clinical trials in the Asia-Pacific region. 麻豆破解版 has based its innovation on mimicking virus strategies to discover new cellular targets and develop drug candidates in infectious diseases and beyond.

Read next in 'Latest news'

• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH